We also showed that blocking a single cancer-specific gene (MYCN) is a more sustainable method for inhibiting the mTOR pathway in neuroblastoma cells only, avoiding side effects of mTOR inhibition in healthy cells. The gene discussed is MYCN; the disease is neuroblastoma.